• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ShouTi Appoints Sharon Tetlow to Board of Directors

    3/29/22 8:00:00 AM ET
    $CBIO
    $DICE
    $VALN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBIO alert in real time by email

    ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee.

    "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspective will help propel us into our next stage of growth in bringing more effective and globally-accessible treatments to patients with chronic diseases."

    Ms. Tetlow has more than 30 years of financial leadership experience within the life sciences industry. She founded and serves as Managing Partner of Potrero Hill Advisors (PHA). Prior to PHA, Ms. Tetlow held numerous senior finance roles, including Chief Financial Officer, at multiple public and private life sciences companies. Ms. Tetlow is an experienced board director and currently serves as board member, Audit Committee Chair and member of the Nominating and Governance Committee of Dice Therapeutics (NASDAQ:DICE), as Supervisory Board Member and Audit Committee Chair of Valneva SE (NASDAQ:VALN) and as board member and Audit Committee Chair of Catalyst Biosciences (NASDAQ:CBIO). Ms. Tetlow earned a B.A. from the University of Delaware, and an M.B.A. from Stanford University.

    "With its powerful structure-based drug discovery engine and pipeline of novel small molecule drug candidates, I believe ShouTi has a unique opportunity to bring impactful medicines to the world," said Ms. Tetlow. "I'm excited to join the ShouTi board to help shape the company's evolution and drive our mission of developing innovative oral therapeutics to treat a wide range of diseases within the metabolic, cardiovascular and pulmonary therapeutic areas."

    About ShouTi

    ShouTi is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. ShouTi's pipeline includes two clinical compounds. The company's cutting-edge technology platform leverages structure-based drug discovery and computational chemistry expertise and enables ShouTi to develop oral small molecule therapeutics for the treatment of various diseases, including those in the metabolic, cardiovascular, and pulmonary therapeutic areas. By leveraging ShouTi's world-class structure-based drug discovery know-how, the company aims to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies, starting with a focus on the GPCR family of drug targets. For more information, visit www.shoutipharma.com and follow the company on Twitter @ShouTiPharma and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005140/en/

    Get the next $CBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBIO
    $DICE
    $VALN

    CompanyDatePrice TargetRatingAnalyst
    DICE Therapeutics Inc.
    $DICE
    5/24/2023$38.00Equal Weight
    Wells Fargo
    DICE Therapeutics Inc.
    $DICE
    5/22/2023$71.00Buy
    Canaccord Genuity
    DICE Therapeutics Inc.
    $DICE
    3/31/2023$56.00Buy
    Needham
    DICE Therapeutics Inc.
    $DICE
    3/1/2023Outperform
    TD Cowen
    DICE Therapeutics Inc.
    $DICE
    3/1/2023Outperform
    Cowen
    DICE Therapeutics Inc.
    $DICE
    11/15/2022$65.00Buy
    Guggenheim
    DICE Therapeutics Inc.
    $DICE
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    DICE Therapeutics Inc.
    $DICE
    9/7/2022$37.00Buy
    Stifel
    More analyst ratings

    $CBIO
    $DICE
    $VALN
    Financials

    Live finance-specific insights

    See more
    • Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

      5/7/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

      Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), March 20, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its consolidated financial results for the y

      3/20/25 2:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

       Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D budget for partnered Lyme disease program were completed in the second quarter of the year Full-year 2024 Financial Guidance Narrowed Expected total product sales according to guidan

      11/7/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBIO
    $DICE
    $VALN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on DICE Therapeutics with a new price target

      Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00

      5/24/23 7:49:57 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on DICE Therapeutics with a new price target

      Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00

      5/22/23 7:17:25 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on DICE Therapeutics with a new price target

      Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00

      3/31/23 7:20:41 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBIO
    $DICE
    $VALN
    SEC Filings

    See more
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      5/7/25 12:11:21 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      4/28/25 7:49:20 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      4/18/25 6:49:09 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBIO
    $DICE
    $VALN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

      Saint Herblain (France), May, 07 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ® for people from 12 to 64 years of age. The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17

      5/7/25 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

      5/7/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

      Saint Herblain (France), April 26, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000

      4/26/25 1:10:00 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBIO
    $DICE
    $VALN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Luo Ying acquired 2,840,376 shares (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:55:53 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ye Weiguo

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:49:12 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ma Songjiang

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:40:34 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBIO
    $DICE
    $VALN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Valneva SE

      SC 13D/A - Valneva SE (0001836564) (Subject)

      9/20/24 4:00:37 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      2/14/24 1:18:41 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Valneva SE (Amendment)

      SC 13G/A - Valneva SE (0001836564) (Subject)

      2/14/24 8:59:33 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBIO
    $DICE
    $VALN
    Leadership Updates

    Live Leadership Updates

    See more
    • Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

      Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director to its Board. Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. Guyot-Caparros has a proven track record in finance and business

      6/26/24 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

      Saint-Herblain (France), May 21, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva's pre-clinical and translational R&D activities in support of the Company's strategic ambition to provide first-, best- or only-in-class vaccine solutions. Dr. Schuitemaker brings more than two decades of experience in vacc

      5/21/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

      EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

      12/15/23 9:04:00 AM ET
      $CBIO
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care